Technical Analysis for ALLK - Allakos Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 0.90 | -4.02% | -0.04 |
ALLK closed down 7.01 percent on Wednesday, November 20, 2024, on 88 percent of normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Very Strong | Down | Flat | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Resistance | Bearish | -4.02% | |
| Wide Bands | Range Expansion | -4.02% | |
| Below Lower BB | Weakness | -4.02% | |
| Down 3 Days in a Row | Weakness | -4.02% | |
| Down 4 Days in a Row | Weakness | -4.02% | |
| Down 5 Days in a Row | Weakness | -4.02% | |
| Lower Bollinger Band Touch | Weakness | -4.02% | |
| Oversold Stochastic | Weakness | -4.02% | |
| Fell Below 200 DMA | Bearish | -10.75% | |
| Wide Bands | Range Expansion | -10.75% |
| Alert | Time |
|---|---|
| 50 DMA Support | about 2 hours ago |
| Down 3% | about 2 hours ago |
| Fell Below Previous Day's Low | about 2 hours ago |
| Down 2 % | about 2 hours ago |
| Down 1% | about 2 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/11/2024
Allakos, Inc. is a clinical-stage biotechnology company, which is engaged in developing antibodies that selectively target mast cells and eosinophils. The Company's antibodies target receptor molecules present on the surface of immune effector cells, which are involved in allergy, inflammation and tissue damage. Its lead program is AK002, which is an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. The Company's AK002 is used in the treatment of various diseases with abnormal proliferation of mast cells, including eosinophilic gastritis (EG), indolent systemic mastocytosis, urticaria and allergic conjunctivitis.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biology Disease Immunology Immune System Antibodies Inflammation Antibody Cell Biology Allergy Allergic Conjunctivitis Mast Cell Mastocytosis Systemic Mastocytosis Eosinophil
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biology Disease Immunology Immune System Antibodies Inflammation Antibody Cell Biology Allergy Allergic Conjunctivitis Mast Cell Mastocytosis Systemic Mastocytosis Eosinophil
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.405 |
| 52 Week Low | 0.535 |
| Average Volume | 759,854 |
| 200-Day Moving Average | 1.04 |
| 50-Day Moving Average | 0.90 |
| 20-Day Moving Average | 1.25 |
| 10-Day Moving Average | 1.22 |
| Average True Range | 0.14 |
| RSI (14) | 40.83 |
| ADX | 50.98 |
| +DI | 21.11 |
| -DI | 19.16 |
| Chandelier Exit (Long, 3 ATRs) | 1.13 |
| Chandelier Exit (Short, 3 ATRs) | 1.27 |
| Upper Bollinger Bands | 1.51 |
| Lower Bollinger Band | 0.99 |
| Percent B (%b) | -0.09 |
| BandWidth | 42.11 |
| MACD Line | 0.04 |
| MACD Signal Line | 0.11 |
| MACD Histogram | -0.0656 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.13 | ||||
| Resistance 3 (R3) | 1.14 | 1.09 | 1.10 | ||
| Resistance 2 (R2) | 1.09 | 1.04 | 1.09 | 1.09 | |
| Resistance 1 (R1) | 1.02 | 1.01 | 0.99 | 1.00 | 1.08 |
| Pivot Point | 0.96 | 0.96 | 0.95 | 0.96 | 0.96 |
| Support 1 (S1) | 0.89 | 0.91 | 0.86 | 0.88 | 0.80 |
| Support 2 (S2) | 0.84 | 0.88 | 0.83 | 0.79 | |
| Support 3 (S3) | 0.76 | 0.84 | 0.78 | ||
| Support 4 (S4) | 0.75 |
